Compare AU
Compare SFY vs. DRUG
Compare shares and ETFs on the ASX that you can trade on Pearler.
Overview
When it comes to investing in the Australian stock market, Exchange-Traded Funds (ETFs) are a popular choice. Two well-known options in the Australian Securities Exchange (ASX) are the SPDR S&P/ASX 50 ETF (SFY) and the Betashares Global Healthcare Currency Hedged ETF (DRUG). In this comparison, we'll delve into these ETFs across various dimensions to help you make an informed investment decision.
Community Stats
SFY | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 19 | 65 |
Median incremental investment | $687.60 | $990.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,444.20 | $1,976.33 |
Average age group | 26 - 35 | 26 - 35 |
Key Summary
SFY | DRUG | |
|---|---|---|
Strategy | SFY.AX was created on 2001-08-24 by SPDR. The fund's investment portfolio concentrates primarily on total market equity. The ETF currently has 739.7m in AUM and 51 holdings. The SPDR S&P/ASX 50 ETF, seeks to closely track, before fees and expenses, the returns of the S&P/ASX 50 Index. | DRUG.AX was created on 2016-08-04 by BetaShares. The fund's investment portfolio concentrates primarily on health care equity. DRUG.AX aims to track the performance of an index (before fees and expenses) that comprises the largest global healthcare companies (ex-Australia), hedged into Australian dollars. |
Top 3 holdings | Commonwealth Bank of Australia (14.18 %) BHP Group Ltd (9.93 %) CSL Ltd (6.03 %) | BRL - BRAZILIAN REAL (0 %) AUD - AUSTRALIA DOLLAR (0 %) CHF - SWISS FRANC (0 %) |
Top 3 industries | Financials (56.05 %) Materials (16.46 %) Health Care (10.34 %) | Other (76.17 %) Communication Services (33.53 %) Health Care (23.66 %) |
Top 3 countries | Australia (95.68 %) United States (2.73 %) New Zealand (1.11 %) | United States (71.71 %) Switzerland (8.14 %) Denmark (6.30 %) |
Management fee | 0.2 % | 0.57 % |
Key Summary
SFY | DRUG | |
|---|---|---|
Issuer | SPDR | BetaShares |
Tracking index | S&P/ASX 50 Index - AUD | Nasdaq Global ex-Australia Healthcare Hedged AUD Index - AUD |
Asset class | ETF | ETF |
Management fee | 0.2 % | 0.57 % |
Price | $72.21 | $7.69 |
Size | $739.261 million | $169.381 million |
10Y return | 32.42 % | N/A |
Annual distribution yield (5Y) | 5.78 % | 1.89 % |
Market | ASX | ASX |
First listed date | 27/08/2001 | 08/08/2016 |
Purchase fee | $6.50 | $6.50 |
Community Stats
SFY | DRUG | |
|---|---|---|
Popularity | Low | Low |
Pearlers invested | 19 | 65 |
Median incremental investment | $687.60 | $990.50 |
Median investment frequency | Monthly | Monthly |
Median total investment | $1,444.20 | $1,976.33 |
Average age group | 26 - 35 | 26 - 35 |
Pros and Cons
SFY | DRUG | |
|---|---|---|
Pros |
|
|
Cons |
|
|
SFY | DRUG |
|---|---|
Higher exposure to AU market | Lower exposure to AU market |
Lower exposure to US market | Higher exposure to US market |
Lower management fee | Higher management fee |
Higher price growth | Lower price growth |
Higher distribution yield | Lower distribution yield |